^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BMS-986403
i
Other names: BMS-986403, BMS986403, BMS 986403
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BMS
Drug class:
ROR1-targeted CAR-T immunotherapy
Related drugs:
over1year
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
P1, N=5, Terminated, Bristol-Myers Squibb | N=65 --> 5 | Trial completion date: Mar 2025 --> May 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2025 --> May 2023; Business objectives have changed.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
cyclophosphamide • fludarabine IV • BMS-986403
over1year
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
P1, N=65, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting | Trial completion date: Jan 2029 --> Mar 2025 | Trial primary completion date: Jan 2029 --> Mar 2025
Enrollment closed • Trial completion date • Trial primary completion date
|
cyclophosphamide • fludarabine IV • BMS-986403
Share via
